Literature DB >> 7578400

The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines.

D W Russell1, M S Berger, A D Miller.   

Abstract

Human serum is known to inactivate many retroviruses, including murine leukemia viruses (MLV). Exposure of vectors based on MLV to human serum components would presumably decrease the efficiency of gene transfer in vivo. Human serum also lyses xenogeneic cells, which would affect the survival of retroviral vector packaging cells in vivo. The effects of other body fluids, such as cerebrospinal fluid (CSF), on MLV vectors and packaging lines have not been studied. We have found that retroviral vectors packaged in ecotropic, amphotropic, and gibbon ape leukemia virus (GALV) envelope proteins were all inactivated by human sera, and human sera also lysed mouse NIH-3T3 cells and the retroviral vector packaging cells derived from them. Human fibroblasts producing amphotropic vector particles were resistant to lysis, but the particles produced by them were inactivated. In contrast, CSF did not inactivate MLV vectors, nor did it lyse murine retrovirus packaging cells. Our results suggest that exposure to human serum may prevent in vivo gene transfer by MLV vectors and xenogeneic packaging lines, but gene transfer within the central nervous system should be more successful.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7578400     DOI: 10.1089/hum.1995.6.5-635

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  8 in total

Review 1.  Adeno-associated virus vectors and hematology.

Authors:  D W Russell; M A Kay
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

Review 2.  Liver-directed gene transfer and application to therapy.

Authors:  V Sandig; M Strauss
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

3.  The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent.

Authors:  N J DePolo; C E Harkleroad; M Bodner; A T Watt; C G Anderson; J S Greengard; K K Murthy; T W Dubensky; D J Jolly
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

4.  Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions.

Authors:  R K Batra; J C Olsen; D K Hoganson; B Caterson; R C Boucher
Journal:  J Biol Chem       Date:  1997-05-02       Impact factor: 5.157

Review 5.  Clinical trials with retrovirus mediated gene therapy--what have we learned?

Authors:  Nikolai G Rainov; Huan Ren
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.130

6.  Foamy virus vectors.

Authors:  D W Russell; A D Miller
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

7.  PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum.

Authors:  Maria A Croyle; Shellie M Callahan; Alberto Auricchio; Gregg Schumer; Klause D Linse; James M Wilson; Lane J Brunner; Gary P Kobinger
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

8.  Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas.

Authors:  Isabelle M Germano; Jennifer Fable; S Humayun Gultekin; Adam Silvers
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.506

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.